|
rs1695
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Genetic polymorphisms such as ERCC1 8092C>A, ABCB1 2677G>T/A, GSTP1 I105V and GSTT1 polymorphisms may affect drug response, toxicity and survival in patient with EOC who received taxane- and platinum-based chemotherapy after surgery.
|
19203783 |
2009 |
|
rs2228570
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The rs2228570 polymorphism increased the risk of ovarian cancer in Caucasian populations in a dominant genetic model.
|
29239065 |
2018 |
|
rs2228570
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The homozygote model with the rs2228570 (FokI) polymorphism model appeared to detect the risk of OC in all cases, whereas the heterozygote model with the rs1544410 (BsmI) polymorphism seemed to detect the risk of OC in Caucasian patients.
|
30059751 |
2018 |
|
rs13181
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The present study suggests that the ERCC2 gene rs13181 polymorphism might be associated with increased risk of ovarian cancer.
|
28676967 |
2017 |
|
rs2228570
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The VDR polymorphism FokI (rs2228570) seems to increase the risk of ovarian cancer.
|
29113037 |
2017 |
|
rs13181
|
|
|
0.050 |
GeneticVariation |
BEFREE |
In conclusion, this meta-analysis indicates that XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms may not be associated with the risk of OC.
|
27863412 |
2016 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian cancer exhibiting PTEN loss and PIK3CA amplification demonstrated partial response by RECIST and GCIG-CA125 criteria, respectively.
|
25370471 |
2015 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
|
26490654 |
2015 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian cancer exhibiting PTEN loss and PIK3CA amplification demonstrated partial response by RECIST and GCIG-CA125 criteria, respectively.
|
25370471 |
2015 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
|
26490654 |
2015 |
|
rs13181
|
|
|
0.050 |
GeneticVariation |
BEFREE |
In addition, our work also points out the importance of new studies for Lys751Gln association in endometrial cancer and ovarian cancer, where at least some of the covariates responsible for heterogeneity could be controlled, to obtain a more conclusive understanding about the function of the Lys751Gln polymorphism in cancer development.
|
25113251 |
2014 |
|
rs2228570
|
|
|
0.050 |
GeneticVariation |
BEFREE |
More studies are warranted to assess the association between the VDR rs2228570 polymorphism and ovarian cancer in Asians and Africans.
|
24136742 |
2014 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The presence of the BRAF V600E mutation in SB/LGS ovarian cancer was associated with early stage disease and improved prognosis.
|
22930283 |
2013 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The presence of the BRAF V600E mutation in SB/LGS ovarian cancer was associated with early stage disease and improved prognosis.
|
22930283 |
2013 |
|
rs13181
|
|
|
0.050 |
GeneticVariation |
BEFREE |
There are no associations between the XPC PAT+/-, XRCC1 Arg194Trp, Arg280His, Arg399Gln, and XPD Asp312Asn, Lys751Gln polymorphisms and the survival of patients with epithelial ovarian cancer when treated with platinum-based chemotherapy.
|
23621265 |
2013 |
|
rs13181
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The aim of the present study was to evaluate the role of SNPs in three genes, XRCC2 (R188H), ERCC2 (K751Q) and CDKN1B (V109G) which are with moderate risk for ovarian cancer susceptibility in Egyptian women.
|
23277402 |
2013 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
One recurrent somatic mutation, p.V600E, is frequently found in several tumor types, such as melanoma, papillary thyroid carcinoma, colon cancer, and ovarian cancer.
|
20735442 |
2011 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
One recurrent somatic mutation, p.V600E, is frequently found in several tumor types, such as melanoma, papillary thyroid carcinoma, colon cancer, and ovarian cancer.
|
20735442 |
2011 |
|
rs2228570
|
|
|
0.050 |
GeneticVariation |
BEFREE |
This pooled analysis provides further evidence that the VDR rs2228570 polymorphism might influence ovarian cancer susceptibility.
|
20473893 |
2011 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Germ line and somatic mutations of BRAF V599E in ovarian carcinoma.
|
17309670 |
2007 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Germ line and somatic mutations of BRAF V599E in ovarian carcinoma.
|
17309670 |
2007 |
|
rs2070074
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We conclude that the GALT N314D allele does not predispose to epithelial ovarian cancer.
|
12869412 |
2003 |
|
rs2070074
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Association of galactose-1-phosphate uridyltransferase activity and N314D genotype with the risk of ovarian cancer.
|
12370157 |
2002 |
|
rs2070074
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We found no effect of N314D GALT genotype on the risk of borderline ovarian cancer (odds ratio (OR)=0.91; 95% confidence interval (CI)=0.54-1.6) or invasive ovarian cancer (OR=0.78; 95% CI= 0.53-1.2).
|
11936817 |
2002 |
|
rs2070074
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The difference was most evident for endometrioid and clear cell types of ovarian cancer, in which 3.9% of cases were found to be homozygous for N314D compared with 0.4% of controls, yielding an odds ratio and 95% confidence interval of 14.17 (2.62-76.60).
|
10667469 |
2000 |